-
Company Insights
New![]()
Innovation and Patenting activity of IHS Markit Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of IHS Markit Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Danavorexton in Idiopathic Hypersomnia (IH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Danavorexton in Idiopathic Hypersomnia (IH) Drug Details: Danavorexton is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pitolisant Hydrochloride in Idiopathic Hypersomnia (IH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pitolisant Hydrochloride in Idiopathic Hypersomnia (IH) Drug Details: Pitolisant hydrochloride (Wakix, Ozawade) is a central...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ALKS-2680 in Idiopathic Hypersomnia (IH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ALKS-2680 in Idiopathic Hypersomnia (IH) Drug Details: ALKS-2680 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Mazindol ER in Idiopathic Hypersomnia (IH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Mazindol ER in Idiopathic Hypersomnia (IH) Drug Details: Mazindol ER is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Golexanolone in Idiopathic Hypersomnia (IH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Golexanolone in Idiopathic Hypersomnia (IH) Drug Details: Golexanolone (GR-3027) (CVXL-0060) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pentylenetetrazol in Idiopathic Hypersomnia (IH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Pentylenetetrazol in Idiopathic Hypersomnia (IH) Drug Details: Pentylenetetrazol (PTZ) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – DSP-0187 in Idiopathic Hypersomnia (IH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. DSP-0187 in Idiopathic Hypersomnia (IH) Drug Details: DSP-0187 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KP-1077 in Idiopathic Hypersomnia (IH)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KP-1077 in Idiopathic Hypersomnia (IH) Drug Details: KP-1077 is under development for the treatment of...
-
Sector Analysis
![]()
Idiopathic Hypersomnia (IH) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Idiopathic Hypersomnia (IH) Marketed and Pipeline Drugs Report Overview Idiopathic Hypersomnia (IH) is a rare chronic sleep disorder with the primary complaint being the irresistible need to sleep and waking up non-refreshed despite the prolonged duration of sleep, for at least three months. IH belongs to the primary sleep disorder category of hypersomnia. Primary hypersomnia includes narcolepsy type 1 and type 2, and Kleine-Levin syndrome, which commonly occurs in teenage males along with IH. Key Mechanism of Action (Marketed) ·      ...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.